Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra

 

PDF Download Buy Article Permissions and Reprints

Summary

Myocardial function is impaired in rheumatoid arthritis (RA). Inhibition of interleukin (IL)-1 activity reduces experimental myocardial infarction by limiting apoptosis. We investigated whether a) soluble apoptotic markers are related with impaired left ventricular (LV) performance and b) treatment with anakinra, an IL-1 receptor antagonist, reduces apoptotic markers leading to improved LV performance in RA. We studied 46 RA patients. In an acute, double-blind cross-over trial, 23 patients were randomised to a single injection of anakinra or placebo and after 48 hours (h) to the alternative treatment. In a chronic trial, 23 patients who received anakinra for 30 days were compared with 23 patients who received prednisolone. At baseline, 3 h and 30 days after treatment, we measured circulating IL-1β, tumour necrosis factor (TNF)-α, Fas, Fas-ligand and caspase-9 to assess apoptosis. At baseline and 30 days after treatment, we assessed LV longitudinal strain, strain rate and E/Em ratio using 2D-speckle tracking and tissue Doppler echocardiography. At baseline, increased apoptotic markers were related with reduced LongSRS and increased E/Em (p<0.05). After 3 h and 30 days of anakinra, there was a reduction in Fas (median 481 vs. 364 vs. 301 pg/ml), Fasligand (median 289 vs. 221 vs. 190 pg/ml), caspase-9 (median 1.90 vs. 1.40 vs. 1.07 ng/ml), TNF-α and IL-1β (p<0.05 for all comparisons). E/Em, LongS and LongSRS were improved after anakinra (p<0.01) and their percent changes were related with the corresponding changes of Fas and caspase-9 (p<0.05). No changes of the examined parameters were observed after prednisolone. In conclusion, inhibition of IL-1 activity by anakinra reduces apoptotic markers leading to improved LV performance in RA.

• References

• 1 Lee Y, Gustafsson Å. Role of apoptosis in cardiovascular disease. Apoptosis 2009; 14: 536-548.
  CrossrefPubMedGoogle Scholar
• 2 Bryant D. et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998; 97: 1375-1381.
  CrossrefPubMedGoogle Scholar
• 3 Sayen MR. et al. Calcineurin transgenic mice have mitochondrial dysfunction and elevated superoxide production. Am JPhysiol Cell Physiol 2003; 284: C562-C570.
  PubMedGoogle Scholar
• 4 Wang J. et al. Increased in vivo apoptosis in cells lacking mitochondrial DNAgene expression. Proc Natl Acad Sci USA 2001; 98: 4038-4043.
  CrossrefPubMedGoogle Scholar
• 5 Tsuboi M. et al. Tumor necrosis factor-alpha and interleukin-1beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med 1999; 134: 222-231.
  CrossrefPubMedGoogle Scholar
• 6 Lemonnier J. et al. Increased osteoblast apoptosis in apert craniosynostosis: role of protein kinase C and interleukin 1. Am J Pathol 2001; 158: 1833-1842.
  CrossrefPubMedGoogle Scholar
• 7 Chen D-Y. et al. Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still’s disease. Clin Rheumatol 2007; 26: 393-400.
  CrossrefPubMedGoogle Scholar
• 8 Ates A. et al. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis. Clin Rheumatol 2004; 23: 421-425.
  CrossrefPubMedGoogle Scholar
• 9 Nozawa K. et al. Soluble Fas (APO-1, CD95) and solubleFas ligand in rheumatic diseases. Arthritis Rheum 1997; 40: 1126-1129.
  CrossrefPubMedGoogle Scholar
• 10 Tanaka M. et al. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995; 14: 1129-1135.
  PubMedGoogle Scholar
• 11 Yamagouchi S. et al. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am J Cardiol 1999; 83: 1500-1503.
  CrossrefPubMedGoogle Scholar
• 12 Okuyama M. et al. Serum levels of soluble form of Fas molecule in patients with congestive heart failure. Am J Cardiol 1997; 79: 1698-1701.
  CrossrefPubMedGoogle Scholar
• 13 Adamopoulos S. et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006; 98: 102-106.
  CrossrefPubMedGoogle Scholar
• 14 Ikonomidis I. et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008; 117: 2662-2669.
  CrossrefPubMedGoogle Scholar
• 15 Ikonomidis I. et al. Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart 2009; 95: 1502-1507.
  CrossrefPubMedGoogle Scholar
• 16 Ikonomidis I. et al. Inflammatory markers for risk stratification in primary prevention of cardiovascular disease: time for a 'multimarker' approach?. Thromb Haemost 2006; 95: 397-398.
  Article in Thieme ConnectPubMedGoogle Scholar
• 17 Takahashi T. et al. Neutrophil-activating activity and platelet-activating factor synthesis in cytokine-stimulated endothelial cells: reduced activity in growth-arrested cells. Microvasc Res 2007; 73: 29-34.
  CrossrefPubMedGoogle Scholar
• 18 Kaur H, Halliwell B. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Letters 1994; 350: 9-12.
  CrossrefPubMedGoogle Scholar
• 19 Peluffo G, Radi R. Biochemistry of protein tyrosine nitration in cardiovascular pathology. Cardiovasc Res. 2007; 75: 291-302.
  CrossrefPubMedGoogle Scholar
• 20 Dinarello CA. Interleukin-1 and Interleukin-1 antagonism. Blood 1991; 77: 1627-1652.
  PubMedGoogle Scholar
• 21 Bujak M, Frangogiannis NG. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz) 2009; 57: 165-176.
  CrossrefPubMedGoogle Scholar
• 22 Sironi M. et al. IL-1 stimulates IL-6 production in endothelial cells. J Immunol 1989; 142: 549-553.
  PubMedGoogle Scholar
• 23 Abbate A. et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008; 117: 2670-2683.
  CrossrefPubMedGoogle Scholar
• 24 Lekakis JP. et al. Genetic variations of the endothelial nitric oxide synthase gene are related to increased levels of C-reactive protein and macrophage-colony stimulating-factor in patients with coronary artery disease. Thromb Haemost 2006; 96: 520-528.
  Article in Thieme ConnectPubMedGoogle Scholar
• 25 Tedgui A, Mallat Z. Apoptosis as a determinant of atherothrombosis. Thromb Haemost 2001; 86: 420-426.
  Article in Thieme ConnectPubMedGoogle Scholar
• 26 Katsaros KM. et al. High soluble Fas and soluble Fas Ligand serum levels before stent implantation are protective against restenosis. Thromb Haemost 2011; 105: 883-891.
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Youle RJ, Strasser A. The BCL-2 protein family: opposing activities thatmediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
  CrossrefPubMedGoogle Scholar
• 28 Degterev A. et al. A decade of caspases. Oncogene 2003; 22: 8543-8567.
  CrossrefPubMedGoogle Scholar
• 29 Nesic O. et al. IL-1 receptor antagonist prevents apoptosis and caspase-3 activation afterspinal cord injury. J Neurotrauma 2001; 18: 947-956.
  CrossrefPubMedGoogle Scholar
• 30 Sun CC. et al. Interleukin-1 receptor antagonist (IL-1RA) prevents apoptosisin ex vivo expansion of human limbal epithelial cells cultivatedon human amniotic membrane. Stem Cells 2006; 24: 2130-2139.
  CrossrefPubMedGoogle Scholar
• 31 Garcia JH. et al. Interleukin-1 receptor antagonist decreasesthe number of necrotic neurons in rats with middle cerebral arteryocclusion. Am J Pathol 1995; 147: 1477-1486.
  PubMedGoogle Scholar
• 32 Mulcahy NJ. et al. Delayed administrationof interleukin-1 receptor antagonist protects against transient cerebralischaemia in the rat. Br J Pharmacol. 2003; 140: 471-476.
  CrossrefPubMedGoogle Scholar
• 33 Abbate A. et al. Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction. Am J Cardiol 2010; 105: 1371-1377.
  CrossrefPubMedGoogle Scholar
• 34 Zitta K. et al. Interleukin-1beta regulates cell proliferation and activity of extracellular matrix remodelling enzymes in cultured primary pig heart cells. Biochem Biophys Res Commun. 2010; 399: 542-547.
  CrossrefPubMedGoogle Scholar
• 35 Zell R. et al. TNF-alpha and IL-1alpha inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: evidence for primary impairment of mitochondrial function. Moll Cell Biochem 1997; 177: 61-67.
  CrossrefPubMedGoogle Scholar
• 36 Li S. et al. TNF-a initiated oxidative/nitrative stress mediated cardiomyocyte apoptosis in traumatic animals. Apoptosis 2007; 12: 1795-1802.
  CrossrefPubMedGoogle Scholar
• 37 Tian B. et al. Mechanisms of cytokine induced NO-mediated cardiac fibroblast apoptosis. Am J Physiol Heart Circ Physiol. 2002; 283: H1958-1967.
  CrossrefPubMedGoogle Scholar
• 38 Manea A. NADPH oxidase-derived reactive oxygen species: involvement in vascular physiology and pathology. Cell Tissue Res 2010; 342: 325-339.
  CrossrefPubMedGoogle Scholar
• 39 Kuckleburg CJ. et al. Endothelial cell apoptosis induced by bacteria-activated platelets requires caspase-8 and -9 and generation of reactive oxygen species. Thromb Haemost 2008; 99: 363-372.
  Article in Thieme ConnectPubMedGoogle Scholar
• 40 Raza K. et al. Reversing myocardial microvascular disease in a patient with rheumatoid arthritis. J Rheumatol 2005; 32: 754-756.
  PubMedGoogle Scholar
• 41 Weinstein DM. et al. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol Exp Ther 2000; 294: 396-401.
  PubMedGoogle Scholar
• 42 Ikonomidis I. et al. Additive prognostic value of interleukin-6 at peak phase of dobutamine stress echocardiography in patients with coronary artery disease. A 6-year follow-up study. Am Heart J 2008; 156: 269-276.
  CrossrefPubMedGoogle Scholar
• 43 Carlson DL. et al. Caspase inhibition reduces cardiac myocyte dyshomeostasis and improves cardiac contractile function after major burn injury. J Appl Physiol 2007; 103: 323-330.
  CrossrefPubMedGoogle Scholar